Mosunetuzumab with polatuzumab vedotin: Subgroup analyses in patients (pts) with primary refractory or early relapsed large B-cell lymphoma (LBCL)

被引：0
|
作者：
Assouline, Sarit
Budde, Lihua Elizabeth
Chavez, Julio C.
Diefenbach, Catherine S.
Dorritie, Kathleen Anne
Ghosh, Nilanjan
Olszewski, Adam J.
Lossos, Izidore S.
Mehta, Amitkumar
Modi, Dipenkumar
Naik, Seema
Smith, Stephen Douglas
Makadia, Sneha
Pham, Song
Wu, Hao
Batlevi, Connie Lee
To, Iris
Wei, Michael C.
Kamdar, Manali
机构：
[1] McGill Univ, Jewish Gen Hosp, Montreal, PQ, Canada
[2] City Hope Natl Med Ctr, Duarte, CA USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[4] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA
[5] Univ Pittsburgh, UPMC Hillman Canc Ctr, Pittsburgh, PA USA
[6] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
[7] Brown Univ, Legorreta Canc Ctr, Lifespan Canc Inst, Providence, RI USA
[8] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[9] Univ Alabama Birmingham, Birmingham, AL USA
[10] Wayne State Univ, Barbara Ann Karmanos Canc Inst, Detroit, MI USA
[11] Penn State Univ, Coll Med, Hershey, PA USA
[12] Univ Washington, Fred Hutchinson Canc Ctr, Seattle, WA USA
[13] Genentech Inc, South San Francisco, CA USA
[14] F Hoffmann La Roche Ltd, Mississauga, ON, Canada
[15] Univ Colorado, Aurora, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7021
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase 2 study of polatuzumab vedotin plus bendamustine plus rituximab in relapsed/refractory diffuse large B-cell lymphoma
    Terui, Yasuhito
    Rai, Shinya
    Izutsu, Koji
    Yamaguchi, Motoko
    Takizawa, Jun
    Kuroda, Junya
    Ishikawa, Takayuki
    Kato, Koji
    Suehiro, Youko
    Fukuhara, Noriko
    Ohmine, Ken
    Goto, Hideki
    Yamamoto, Kazuhito
    Kanemura, Nobuhiro
    Ueda, Yasunori
    Ishizawa, Kenichi
    Kumagai, Kyoya
    Kawasaki, Atsuko
    Saito, Tomohisa
    Hashizume, Misato
    Shibayama, Hirohiko
    CANCER SCIENCE, 2021, 112 (07) : 2845 - 2854
  • [32] Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: A phase III bridging study in Chinese patients
    Song, Yuqin
    Zhang, Qingyuan
    Cai, Qingqing
    Song, Yongping
    Zhang, Liling
    He, Pengcheng
    Wang, Li
    Hirata, Jamie
    Musick, Lisa
    Deng, Rong
    Liu, Wenxin
    Wang, Xin
    Zhu, Jun
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2024, 20 (07)
  • [33] Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
    Olszewski, Adam J.
    Eradat, Herbert
    Avigdor, Abraham
    Horowitz, Netanel A.
    Babu, Sunil
    Levi, Itai
    McKinney, Matthew
    Lee, Seung Tae
    Bergua Burgues, Juan Miguel
    Rodriguez Izquierdo, Antonia
    Bastos-Oreiro, Mariana
    Ganzel, Chezi
    Kim, Tae Min
    Jeon, Youngwoo
    Taszner, Michal
    Narkhede, Mayur
    Kim, Won Seog
    Shin, Ho-Jin
    Lavie, David
    Woszczyk, Dariusz
    Dunshee, Diana
    Kapp, Amy V.
    Zhou, Mingzhu
    Batlevi, Connie Lee
    Ead, Wahib
    Sellam, Gila
    Jurczak, Wojciech
    BLOOD, 2023, 142
  • [34] Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study
    Gritti, Giuseppe
    Marlton, Paula
    Phillips, Tycel J.
    Arthur, Christopher
    Bannerji, Rajat
    Corradini, Paolo
    Johnston, Anna
    Seymour, John F.
    Yuen, Sam
    Hirata, Jamie
    Musick, Lisa
    Saha, Sourish
    Croft, Brandon
    Flowers, Christopher
    BLOOD, 2020, 136
  • [35] Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: no ordinary subgroup analysis
    Russler-Germain, David A.
    Cliff, Edward R. Scheffer
    Bartlett, Nancy L.
    BLOOD, 2023, 142 (25) : 2216 - 2219
  • [36] Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
    Tilly, Herve
    Morschhauser, Franck
    Sehn, Laurie H.
    Friedberg, Jonathan W.
    Trneny, M.
    Sharman, Jeff P.
    Herbaux, Charles
    Burke, John M.
    Matasar, Matthew
    Rai, Shinya
    Izutsu, Koji
    Mehta-Shah, Neha
    Oberic, Lucie
    Chauchet, Adrien
    Jurczak, Wojciech
    Song, Yuqin
    Greil, Richard
    Mykhalska, Larysa
    Bergua-Burgues, Juan M.
    Cheung, Matthew C.
    Pinto, Antonio
    Shin, Ho-Jin
    Hapgood, Greg
    Munhoz, Eduardo
    Abrisqueta, Pau
    Gau, Jyh-Pyng
    Hirata, Jamie
    Jiang, Yanwen
    Yan, Mark
    Lee, Calvin
    Flowers, Christopher R.
    Salles, Gilles
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (04): : 351 - 363
  • [37] Polatuzumab vedotin in combination with rituximab and bendamustine (Pola-RB) for relapsed primary cutaneous diffuse large B-cell lymphoma
    Wilms, L.
    Oymanns, M.
    Huenerlituerkoglu, A.
    Dippel, E.
    Assaf, C.
    EUROPEAN JOURNAL OF CANCER, 2022, 173 : S25 - S25
  • [38] Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy
    Argnani, Lisa
    Broccoli, Alessandro
    Pellegrini, Cinzia
    Fabbri, Alberto
    Puccini, Benedetta
    Bruna, Riccardo
    Tisi, Maria Chiara
    Masia, Francesco
    Flenghi, Leonardo
    Nizzoli, Maria Elena
    Musso, Maurizio
    Salerno, Marilena
    Scalzulli, Potito Rosario
    Dessi', Daniela
    Ferrarini, Isacco
    Pennese, Elsa
    Lucchini, Elisa
    Rossi, Francesca Gaia
    Minoia, Carla
    Gherlinzoni, Filippo
    Musto, Pellegrino
    Patti, Caterina
    Stefoni, Vittorio
    Zinzani, Pier Luigi
    HEMASPHERE, 2022, 6 (12): : E798
  • [39] Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience
    Segman, Yafit
    Ribakovsky, Elena
    Avigdor, Abraham
    Goldhecht, Yair
    Vainstein, Vladimir
    Goldschmidt, Neta
    Harlev, Shimrit
    Horwitz, Netanel
    Gutwein, Odit
    Gurion, Ronit
    Itchaki, Gilad
    Abadi, Uri
    Nemets, Anatoly
    Sofer, Orit
    Zektser, Miri
    Tadmor, Tamar
    Dally, Nagib
    Filanovsky, Kalman
    Leiba, Merav
    Sarid, Nadav
    Benyamini, Noam
    Herishanu, Yair
    Ram, Ron
    Perry, Chava
    Avivi, Irit
    LEUKEMIA & LYMPHOMA, 2021, 62 (01) : 118 - 124
  • [40] Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab
    Saburi, Masuho
    Sakata, Masanori
    Kodama, Yousuke
    Uraisami, Keiichi
    Takata, Hiroyuki
    Miyazaki, Yasuhiko
    Wada, Junpei
    Urabe, Shogo
    Ohtsuka, Eiichi
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2023, 63 (03) : 201 - 204
12345